Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of thymosin beta-4 [RGN 352] for the treatment of patients immediately following an acute myocardial infarction

Next Previous
Search
Trial Profile

Phase II trial of thymosin beta-4 [RGN 352] for the treatment of patients immediately following an acute myocardial infarction

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Timbetasin (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Oct 2011 This trial is still on clinical hold, according to a RegeneRx media release.
    • 17 Mar 2011 The US FDA has placed a clinical hold on this trial due to non-compliance of cGMP at a contract manufacturing site.
    • 11 Feb 2011 Status changed from planning to not yet recruiting, based on a RegeneRx Biopharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top